Completed
PHASE3
INTERVENTIONAL
NCT05813925
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1½ years.
Interventions
Name:
Cagrilintide
Type:
DRUG
Description:
Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
Name:
Semaglutide
Type:
DRUG
Description:
Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
Name:
Placebo Semaglutide
Type:
DRUG
Description:
Participants will receive placebo matched to semaglutide
Primary Outcomes
Measure:
Relative Change in Body Weight
TimeFrame:
From baseline (week 0) to end of treatment (week 68)
Description:
Measured in percentage (%)
Trial Information
NCT ID
NCT05813925
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025